Share on StockTwits

Research analysts at CRT Capital initiated coverage on shares of Boston Scientific (NYSE:BSX) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $16.00 price target on the stock. CRT Capital’s target price would suggest a potential upside of 22.89% from the company’s current price. The analysts noted that the move was a valuation call.

Shares of Boston Scientific (NYSE:BSX) opened at 13.02 on Monday. Boston Scientific has a 52 week low of $9.10 and a 52 week high of $14.08. The stock’s 50-day moving average is $12.84 and its 200-day moving average is $13.00. The company has a market cap of $17.221 billion and a P/E ratio of 48.02.

Boston Scientific (NYSE:BSX) last announced its earnings results on Tuesday, April 29th. The company reported $0.16 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.18 by $0.02. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was up .7% on a year-over-year basis. Analysts expect that Boston Scientific will post $0.80 EPS for the current fiscal year.

In other Boston Scientific news, Director Ernest Mario unloaded 10,000 shares of Boston Scientific stock on the open market in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $12.95, for a total transaction of $129,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of other analysts have also recently weighed in on BSX. Analysts at Morgan Stanley initiated coverage on shares of Boston Scientific in a research note on Tuesday, June 10th. They set an “overweight” rating and a $15.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific in a research note on Friday, May 30th. They now have a $14.00 price target on the stock. Finally, analysts at TheStreet upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Thursday, May 1st. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Boston Scientific currently has an average rating of “Buy” and a consensus target price of $14.22.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.